Kite's Tecartus Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
93 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus — — Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe — Kite, a Gilead Company today announced that the European Commission has granted conditional marketing authorization for Tecartus™ . Tecartus is a chimeric antigen receptor T … — 93 Percent of Patients in ZUMA-2 Pivotal Trial Responded to Single Infusion of Tecartus — — Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite ...
Source: investingnews.com